Screener
Trevi Therapeutics, Inc. TRVI Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206390
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $9,941 | $7,811 |
| General and administrative | 4,971 | 3,659 |
| Total operating expenses | 14,912 | 11,470 |
| Loss from operations | (14,912) | (11,470) |
| Other income (expense): | ||
| Interest income, net | 1,696 | 1,125 |
| Other income (expense), net | 4 | (6) |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is Trevi Therapeutics, Inc.'s other operating expenses?
- Trevi Therapeutics, Inc. (TRVI) reported other operating expenses of 1,491,200,000% in Q1 2026.
- How has Trevi Therapeutics, Inc.'s other operating expenses changed year-over-year?
- Trevi Therapeutics, Inc.'s other operating expenses increased by 30.0% year-over-year, from 1,147,000,000% to 1,491,200,000%.
- What is the long-term trend for Trevi Therapeutics, Inc.'s other operating expenses?
- Over 4 years (2021 to 2025), Trevi Therapeutics, Inc.'s other operating expenses has grown at a 11.8% compound annual growth rate (CAGR), from 5,667,900,000% to 8,843,600,000%.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Trevi Therapeutics, Inc.'s other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude